Analyst Price Targets — QGEN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 9, 2026 11:56 am | — | UBS | $52.00 | $50.95 | TheFly | Qiagen price target raised to $52 from $50 at UBS |
| February 6, 2026 2:50 pm | Cathy Ramsey Schulte | Robert W. Baird | $53.00 | $51.17 | TheFly | Qiagen price target raised to $53 from $48.42 at Baird |
| February 6, 2026 1:03 pm | — | Stifel Nicolaus | $50.00 | $51.25 | TheFly | Qiagen price target raised to $50 from $45 at Stifel |
| February 6, 2026 10:39 am | — | Barclays | $58.00 | $51.23 | TheFly | Qiagen price target raised to $58 from $55 at Barclays |
| February 5, 2026 8:44 pm | — | Jefferies | $59.00 | $51.23 | TheFly | Qiagen price target raised to $59 from $57 at Jefferies |
| January 22, 2026 8:09 am | Jan Koch | Deutsche Bank | $54.00 | $55.66 | StreetInsider | Deutsche Bank Downgrades Qiagen NV (QGEN) to Hold |
| December 15, 2025 10:56 am | — | Barclays | $55.00 | $45.26 | TheFly | Qiagen price target raised to $55 from $53 at Barclays |
| October 2, 2025 10:43 am | Catherine Ramsey Schulte | Barclays | $53.00 | $46.32 | TheFly | Qiagen price target lowered to $53 from $55 at Barclays |
| October 17, 2024 5:42 am | Shubhangi Gupt | HSBC | $49.00 | $43.21 | TheFly | Qiagen downgraded to Hold from Buy at HSBC |
| June 27, 2024 4:14 am | Doug Schenkel | Wolfe Research | $50.00 | $41.21 | StreetInsider | Wolfe Research Upgrades Qiagen NV (QGEN) to Outperform |
Latest News for QGEN
Qiagen N.V. (QGEN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Qiagen N.V. (NYSE: QGEN - Get Free Report) saw some unusual options trading activity on Thursday. Investors acquired 8,189 put options on the stock. This is an increase of approximately 460% compared to the average daily volume of 1,463 put options. Institutional Investors Weigh In On Qiagen Institutional investors have recently added to or reduced their
SEATTLE, Wash. & VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for…
QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.
Qiagen N.V. (NYSE: QGEN - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors purchased 40,639 call options on the company. This is an increase of approximately 4,664% compared to the average volume of 853 call options. Key Qiagen News Here are the key news stories impacting Qiagen this
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for QGEN.
Senate Trading
No Senate trades found for QGEN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.